FIELD: medicine.
SUBSTANCE: invention relates to experimental radiotherapy and can be used to determine accumulated absorbed doses from β-radiation of the radiopharmaceutical in organs and tissues of laboratory animals. Organs and tissues in which it is necessary to determine the absorbed doses are preliminarily modelled with the following chambers: blood plasma chamber, knee chamber, hip chamber, rib chamber, cranial chamber, spinal chamber, kidney chamber, thyroid chamber, lung chamber, heart chamber, spleen chamber, stomach chamber, intestinal chamber, thigh muscle chamber. Then activity is measured ANexp(t) simultaneously in all N model chambers on each of four animals for time t not less than 48 hours. At that, values of absorbed doses DN(ti) accumulated by time ti in each of N model chambers are determined from solution of system of differential equations
and transport constants are based on the condition of minimum residual functional
.
If the experimental accuracy of measuring activity is ΔANexp(t)/ANexp(t) in some of the given N chambers is less than the accuracy of simulating the absorbed dose ΔDS(t)/D(t) in them, data of S chambers, except for blood chamber, are excluded from repeated measurements of activity. Thereafter, K-repeated experimental measurements of activity ANSexp(t) in all NS model chambers of organs and tissues on the second and next K group of laboratory animals. At the same time repeated solution of system of differential equations is carried out for calculation of specified transport constants. Experiment and simulation are repeated K times until the accuracy of determining the value of the absorbed dose in organs and tissues is higher and equal to the accuracy of measuring activity in them.
EFFECT: method provides higher accuracy and reliability of measuring absorbed doses in given organs and tissues for determining the suitability of radiopharmaceuticals for treating said organs and tissues as intended by repeating the experiment and modelling K times until the accuracy of determining the value of the absorbed dose in organs and tissues is higher and equal to the accuracy of measuring activity in them.
1 cl, 2 dwg, 10 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
PSMA-TARGET COMPOUND AND ITS COMPLEX WITH RADIONUCLIDES FOR THERANOSTICS OF TUMOR EXPRESSING PSMA | 2022 |
|
RU2803734C1 |
LYOPHILISATE BASED ON PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS FOR PREPARING A RADIOPHARMACEUTICAL COMPOSITION IN FORM OF SOLUTION FOR INJECTIONS FOR TREATING PROSTATE CANCER, RADIOPHARMACEUTICAL COMPOSITION BASED ON IT FOR TREATING PROSTATE CANCER AND METHOD FOR PREPARING RADIOPHARMACEUTICAL COMPOSITION | 2023 |
|
RU2817970C1 |
COMPOUND AND ITS COMPLEX WITH RADIONUCLIDE Lu FOR THERANOSTICS OF TUMORS EXPRESSING ON HER2 RECEPTORS | 2023 |
|
RU2826247C1 |
RADIOPHARMACEUTICAL COMPOSITION | 2000 |
|
RU2162714C1 |
METHOD OF TUMOR DIAGNOSIS | 2017 |
|
RU2657761C1 |
RADIOPHARMACEUTICAL COMPOSITION FOR TREATMENT OF PAIN IN INFLAMMATORY DISEASES OF JOINTS | 2017 |
|
RU2662088C1 |
ANTIBODIES POLYPEPTIDES AND USE THEREOF | 2014 |
|
RU2687163C1 |
METHOD FOR PRODUCING A RADIOPHARMACEUTICAL PREPARATION WITH GALLIUM-68 FOR VISUALISATION OF SKELETAL METASTASES BY THE PET METHOD | 2020 |
|
RU2757258C1 |
METHOD FOR VERIFICATION OF DOSE DURING MEDICAL ADMINISTRATION OF OPEN RADIOACTIVE NUCLIDES | 2005 |
|
RU2289458C2 |
METHOD FOR RADIONUCLIDE DIAGNOSTICS OF MALIGNANT LYMPHOMAS | 2018 |
|
RU2706602C1 |
Authors
Dates
2024-06-28—Published
2022-09-30—Filed